Coherus BioSciences Inc. (NASDAQ: CHRS) is -58.96% lower on its value in year-to-date trading and has touched a low of $5.60 and a high of $19.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CHRS stock was last observed hovering at around $6.55 in the last trading session, with the day’s loss setting it 0.0% off its average median price target of $15.00 for the next 12 months. It is also 78.17% off the consensus price target high of $30.00 offered by 8 analysts, but current levels are 40.45% higher than the price target low of $11.00 for the same period.
Currently trading at $6.55, the stock is -15.90% and -23.86% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.5 million and changing 0.00% at the moment leaves the stock -32.70% off its SMA200. CHRS registered -65.14% loss for a year compared to 6-month gain of -11.61%.
The stock witnessed a -23.66% loss in the last 1 month and extending the period to 3 months gives it a -48.99%, and is -10.88% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.86% over the week and 6.66% over the month.
Coherus BioSciences Inc. (CHRS) has around 376 employees, a market worth around $507.17M and $239.10M in sales. Distance from 52-week low is 16.96% and -65.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-52.00%).
Coherus BioSciences Inc. (CHRS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Coherus BioSciences Inc. (CHRS) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.40, where 3 rate it as a Hold and 1 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
The EPS is expected to shrink by -334.40% this year
Coherus BioSciences Inc. (CHRS) Top Institutional Holders
The shares outstanding are 77.75M, and float is at 71.61M with Short Float at 13.01%.
Coherus BioSciences Inc. (CHRS): Who are the competitors?
The company’s main competitors (and peers) include Affimed N.V. (AFMD) that is trading -69.02% down over the past 12 months and Acorda Therapeutics Inc. (ACOR) that is -80.51% lower over the same period. Repligen Corporation (RGEN) is -36.04% down on the 1-year trading charts.